| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 58,223 | 76,957 | 93,414 | 106,144 |
| Prepaid expenses and other current assets | 6,887 | 3,632 | 1,998 | 1,472 |
| Total current assets | 65,110 | 80,589 | 95,412 | 107,616 |
| Property and equipment, at cost | 241 | 241 | 241 | NaN |
| Less accumulated depreciation | 131 | 112 | 93 | NaN |
| Property and equipment, net | 110 | 129 | 148 | 110 |
| Other assets | 2,003 | 2,061 | 1,529 | 57 |
| Total assets | 67,223 | 82,779 | 97,089 | 107,783 |
| Accounts payable | 13,084 | 9,989 | 5,491 | 5,301 |
| Accrued liabilities | 10,563 | 10,762 | 7,501 | 3,869 |
| Total current liabilities | 23,647 | 20,751 | 12,992 | 9,170 |
| Income tax payable | NaN | 1,037 | NaN | NaN |
| Other liabilities | 1,476 | NaN | NaN | NaN |
| Total liabilities | 25,123 | 21,788 | NaN | NaN |
| Common stock, 0.001 par value 200,000,000 shares authorized as of march 31, 2026 (unaudited) and december 31, 2025 13,910,668 and 12,948,308 shares issued and outstanding as of march 31, 2026 (unaudited) and december 31, 2025, respectively | 14 | 13 | 13 | 12 |
| Additional paid-in capital | 287,599 | 284,348 | 282,675 | 279,504 |
| Accumulated other comprehensive (loss) income | -4 | 3 | -6 | NaN |
| Accumulated deficit | -245,509 | -223,373 | -198,585 | -180,903 |
| Total stockholders equity | 42,100 | 60,991 | 84,097 | 98,613 |
| Total liabilities and stockholders' equity | 67,223 | 82,779 | 97,089 | 107,783 |
Forte Biosciences, Inc. (FBRX)
Forte Biosciences, Inc. (FBRX)